BUSINESS WIRE has reported at London: According to the latest market research report, Technavio analysts predict that the global CAR-T cell therapy market will grow at a compound annual growth rate of more than 63% during the analysis cycle.
Enterprise development trend
Cooperative R&D is one of the main trends in the global market of CAR-T cell therapy from 2018 to 2022. Most therapies in the global market for CAR T cell therapy are still in the early stages of clinical trials. At present, the research is led by biotechnology companies, which have not received the huge amount of funds needed to fully carry out the research. These companies license molecular or technological platforms to pharmaceutical companies, or cooperate with them or various research projects.
Key factors of market growth
According to Technavio analysts, one of the key factors contributing to the growth of the global market for CAR T cell therapy is the effectiveness of CAR-T cell therapy.
Car-T cell therapy has proved to be more effective than other therapies available in the market for cancer treatment. The ability of CAR to integrate into the surface of T cells, especially when delivered by monoclonal antibodies, facilitates T cells to penetrate into patients'carcinogenic cells more easily.
"Kymriah, a CAR-T cell therapy developed by Novartis, is being used to treat a variety of other cancers, such as CLL, multiple myeloma and non-Hodgkin's lymphoma. Its main objective is to improve efficacy while reducing side effects of treatment," said Technavio senior analyst, who is conducting research on infectious and rare diseases.
Market share statistics
This global CAR-T cell therapy market study provides market analysis of antigens (CD19, CD22 and other targets) and regions (Americas, EMEA and APAC). It makes an in-depth analysis of the prominent factors affecting the market, including driving factors, opportunities, trends and industry-specific challenges.
The report points out that the development of CD19 target occupies the largest market share in 2017, with a market share of more than 88%. The report suggests that the antigen fragment will dominate the global market throughout the forecast period.
In 2017, the market share of the Americas was the largest, accounting for more than 64%, followed by Europe, the Middle East, Africa and the Asia-Pacific region. Although the Asia-Pacific region has the smallest market share, its market share is expected to increase substantially during the forecast period.